News
|
|
Cloud Pharmaceuticals to Present AI-Based Drug Design at Conferences in May
COO Don Van Dyke to describe company technology and achievements in designing small molecule and peptide agents.
Research Triangle Park, NC, April 30, 2019
RESEARCH TRIANGLE PARK, NC, USA, April 30, 2019 -- Don Van Dyke, COO of Cloud Pharmaceuticals Inc., an AI-based drug design company, is being featured as a speaker at several conferences in May. Van Dyke will discuss how Artificial Intelligence-based drug design is helping to transform the creation of new medicines.
During his sessions, Van Dyke describe Cloud Pharmaceuticals’ Quantum Molecular Design process, which enables faster progress at lower cost and a higher success rate than traditional methods, even with difficult targets. He will reference the company’s work with companies such as GSK to advance from target to lead molecule in months rather than years.
Schedule:
“We are at the threshold of a revolution in medicine that will be more dramatic than any prior advance,” Van Dyke explains. “Designed drugs may be similar to discovered natural compounds, which will continue to give scientists clues about how nature and evolution have shaped biological interactions. But deeper understanding of the molecular basis for disease will bring about targeted attacks on the functioning of the very molecules that make us sick.”
COO Don Van Dyke to describe company technology and achievements in designing small molecule and peptide agents.
Research Triangle Park, NC, April 30, 2019
RESEARCH TRIANGLE PARK, NC, USA, April 30, 2019 -- Don Van Dyke, COO of Cloud Pharmaceuticals Inc., an AI-based drug design company, is being featured as a speaker at several conferences in May. Van Dyke will discuss how Artificial Intelligence-based drug design is helping to transform the creation of new medicines.
During his sessions, Van Dyke describe Cloud Pharmaceuticals’ Quantum Molecular Design process, which enables faster progress at lower cost and a higher success rate than traditional methods, even with difficult targets. He will reference the company’s work with companies such as GSK to advance from target to lead molecule in months rather than years.
Schedule:
- 4th Drug Discovery Nexus Summit 2019 May 16-17, 2019, Boston, MA.
- 8th DRUG DISCOVERY INNOVATION PROGRAMME May 21, 2019, Boston, MA
- PHARMA AI May 23 - 24, 2019 London, UK
“We are at the threshold of a revolution in medicine that will be more dramatic than any prior advance,” Van Dyke explains. “Designed drugs may be similar to discovered natural compounds, which will continue to give scientists clues about how nature and evolution have shaped biological interactions. But deeper understanding of the molecular basis for disease will bring about targeted attacks on the functioning of the very molecules that make us sick.”
About Cloud Pharmaceuticals, Inc.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
###